7 Cambridge Center<br>Cambridge Massachusetts 02
320 Charles Street
About Broad InstituteThe Broad Institute was launched to pioneer a new model of collaborative biomedical science that would transform medicine. To accomplish these goals, we have built an amazing team of talented “Broadies” who work together to realize this transformation.
We are always looking for new Broadies to join our team and help us tackle important problems at the cutting edge of science.
The Broad community The Broad community includes professional scientists from many disciplines, administrative staff, and students. We seek to cultivate an interdisciplinary, goal-oriented work environment that unleashes scientific creativity and empowers our people to pursue ambitious and critical projects
Our work transcends traditional academic boundaries, giving Broad employees and affiliates access to an unparalleled biomedical research community across the Harvard and MIT communities and beyond.
Benefits of working at Broad The Broad Institute is committed to providing its employees with a competitive compensation and benefits package. We recognize the need for our employees to have a balance between work and personal life. To that end, our benefit plans and options reflect our desire to promote an environment that supports the health, diversity, and general wellbeing of our employees.
All Broadies also have access to world-class research and state of the art technology and are fully supported in their professional development, pushing the envelope for further growth.
The Broad Benefits Program includes:
• Medical • Dental • Basic Life Insurance, Accidental Death & Dismemberment, Business Travel and Supplemental Life Insurance • Short-Term and Long-Term Disability • Flexible Spending Accounts • 401(K) Plan w/Competitive Employer Match • 4 Weeks of Vacation after 1 Year • Tuition Reimbursement • Identity Theft Prevention and Insurance • Estate Planning • Adoption Assistance • Employee Assistance Program (EAP) • MBTA Commuter Transportation Subsidies • Parents in a Pinch Back Up Child Care • Credit Union
The Broad Institute is an equal opportunity employer.
To learn more about the Broad’s job opportunities, visit our Career Center at: https://www.broadinstitute.org/careers/career-center
112 articles with Broad Institute
In the wake of the scandal caused by a Chinese researcher’s use of CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples, leading scientists called for a moratorium on heritable genome editing.
Research Roundup: Gene Therapy for Deafness, Autism Genes, Breakthroughs in Parkinson’s and ALS, ...
3/1/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
New endeavor will advance blood-based biopsies and other technologies to speed cancer diagnosis and track patients' response to therapies
IBM Watson Health and the Broad Institute Launch Initiative to Help Clinicians Predict the Risk of Cardiovascular Disease with Genomics and AI
IBM Watson Health and the Broad Institute of MIT and Harvard are expanding their partnership to help clinicians better predict the possibility of serious cardiovascular diseases.
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
November 30 Research Roundup: CRISPR Embryos, Brain-Computer Interface, ADHD Genetic Variants and...
11/30/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Although most readers will already be aware of it, the biggest story, perhaps the biggest story of the year—certainly the most controversial—involves a Chinese researcher who used CRISPR to m...
11/29/2018Scientists from a consortium of prominent research institutions studied the entire genomes of more than 20,000 people with attention deficit/hyperactivity disorder (ADHD) and compared them to the genomes of 35,000 who did not have ADHD. They identified 12 genetic variants in the ADHD group, sugge...
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
RootPath, headquartered in Cambridge, Massachusetts, announced a $7 million seed funding round. The financing was led by Sequoia China. Volcanics Venture, BV (Baidu Ventures) and NestBio Ventures participated.
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics
Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.
Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round.
Broad Institute Releases Open-Source GATK4 Software for Genome Analysis, Optimized for Speed and Scalability
Today the Broad Institute of MIT and Harvard is releasing version 4.0 of the Genome Analysis Toolkit, the institute's flagship genome variant discovery package for analysis of high-throughput sequencing data.
Syngenta Obtains Non-Exclusive IP License From Broad Institute for CRISPR-Cas9 Genome-Editing Technology for Agriculture Applications
CRISPR-Cas9 genome editing technology complements Syngenta’s already robust plant breeding innovation toolbox
Broad Institute And Deerfield Management Launch Innovative Partnership To Tackle Serious Unmet Medical Needs